# 1 COVID-19-associated hospitalizations among vaccinated and unvaccinated adults ≥18 years – COVID-

## 2 NET, 13 states, January 1 – July 24, 2021

## 3 Authors:

- 4 Fiona P. Havers, MD, MHS<sup>1,2</sup>; Huong Pham, MPH<sup>1</sup>; Christopher A. Taylor, PhD<sup>1</sup>; Michael Whitaker, MPH<sup>1</sup>;
- 5 Kadam Patel, MPH<sup>1,3</sup>; Onika Anglin, MPH<sup>1,3</sup>; Anita K. Kambhampati, MPH<sup>1</sup>; Jennifer Milucky, MSPH<sup>1</sup>;
- 6 Elizabeth Zell, MStat<sup>1,4</sup>; Shua J. Chai, MD, MPH<sup>5,6</sup>; Pam Daily Kirley, MPH<sup>6</sup>; Nisha B. Alden, MPH<sup>7</sup>; Isaac
- 7 Armistead, MD MPH<sup>7</sup>; Kimberly Yousey-Hindes, MPH, CPH<sup>8</sup>; James Meek, MPH<sup>8</sup>; Kyle P. Openo, DrPH<sup>9,10</sup>;
- 8 Evan J. Anderson, MD<sup>10,11,12</sup>; Libby Reeg, MPH<sup>13</sup>; Alexander Kohrman, MPH<sup>13</sup>; Ruth Lynfield, MD<sup>14</sup>;
- 9 Kathryn Como-Sabetti, MPH<sup>14</sup>; Elizabeth M. Davis, MA<sup>15</sup>; Cory Cline, MPH<sup>15</sup>; Alison Muse, MPH<sup>16</sup>; Grant
- Barney, MPH<sup>16</sup>; Sophrena Bushey, MHS<sup>17</sup>; Christina B. Felsen, MPH<sup>17</sup>; Laurie M. Billing, MPH<sup>18</sup>; Eli Shiltz,
- 11 MPH<sup>18</sup>; Melissa Sutton, MD, MPH<sup>19</sup>; Nasreen Abdullah, MD, MPH<sup>19</sup>; H. Keipp Talbot, MD, MPH<sup>20</sup>; William
- 12 Schaffner, MD<sup>20</sup>; Mary Hill, MPH<sup>21</sup>; Andrea George, MPH<sup>21</sup>; Bhavini Patel Murthy, MD<sup>1,2</sup>; Meredith
- 13 McMorrow, MD, MPH<sup>1,2</sup>

# 14 Affiliations:

- 15 <sup>1</sup> CDC COVID-19 Response, Atlanta, GA
- 16 <sup>2</sup> United States Public Health Service Commissioned Corps, Rockville, MD
- 17 <sup>3</sup> General Dynamics Information Technology, Atlanta, GA
- 18 <sup>4</sup> Stat-Epi Associates, Inc., Ponte Vedra Beach, FL
- <sup>5</sup> Division of State and Local Readiness, Center for Preparedness and Response, Centers for Disease
- 20 Control and Prevention, Atlanta, GA
- 21 <sup>6</sup> California Emerging Infections Program, Oakland, CA
- 22 <sup>7</sup> Colorado Department of Public Health and Environment, Denver, CO
- 23 <sup>8</sup>Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, CT
- <sup>9</sup> Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, GA
- <sup>10</sup> Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta, GA
- 26 <sup>11</sup> Departments of Medicine and Pediatrics, Emory School of Medicine, Atlanta, GA
- 27 <sup>12</sup> Atlanta Veterans Affairs Medical Center, Atlanta, GA
- 28 <sup>13</sup> Michigan Department of Health and Human Services, Lansing, MI
- 29 <sup>14</sup> Minnesota Department of Health, St. Paul, MN
- 30 <sup>15</sup> New Mexico Department of Health, Santa Fe, NM
- 31 <sup>16</sup> New York State Department of Health, Albany, NY
- 32 <sup>17</sup> University of Rochester School of Medicine and Dentistry, Rochester, NY
- 33 <sup>18</sup> Ohio Department of Health, Columbus, OH
- 34 <sup>19</sup> Public Health Division, Oregon Health Authority, Portland, OR
- 35 <sup>20</sup> Vanderbilt University Medical Center, Nashville, TN
- 36 <sup>21</sup> Salt Lake County Health Department, Salt Lake City, UT
- 37
- 38
- 39 Corresponding author:
- 40 Fiona Havers, MD, MHS
- 41 1600 Clifton RD, MS H24-6

- 42 Atlanta, GA 30329
- 43 Phone: 404-639-5062; Email: <u>fhavers@cdc.gov</u>
- 44
- 45
- 46 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily
- 47 represent the views of the U.S. Centers for Disease Control and Prevention.

## 48 Abstract

49	<b>Background:</b> As of August 21, 2021, >60% of the U.S. population aged ≥18 years were fully vaccinated
50	with vaccines highly effective in preventing hospitalization due to Coronavirus Disease-2019 (COVID-19).
51	Infection despite full vaccination (vaccine breakthrough) has been reported, but characteristics of those
52	with vaccine breakthrough resulting in hospitalization and relative rates of hospitalization in
53	unvaccinated and vaccinated persons are not well described, including during late June and July 2021
54	when the highly transmissible Delta variant predominated.
55	<b>Methods:</b> From January 1–June 30, 2021, cases defined as adults aged ≥18 years with laboratory-
56	confirmed Severe Acute Respiratory Coronavirus-2 (SARS-CoV-2) infection were identified from >250
57	acute care hospitals in the population-based COVID-19-Associated Hospitalization Surveillance Network
58	(COVID-NET). Through chart review for sampled cases, we examine characteristics associated with
59	vaccination breakthrough. From January 24–July 24, 2021, state immunization information system data
60	linked to both >37,000 cases representative cases and the defined surveillance catchment area
61	population were used to compare weekly hospitalization rates in vaccinated and unvaccinated
62	individuals. Unweighted case counts and weighted percentages are presented.
63	<b>Results:</b> From January 1 – June 30, 2021, fully vaccinated cases increased from 1 (0.01%) to 321 (16.1%)
64	per month. Among 4,732 sampled cases, fully vaccinated persons admitted with COVID-19 were older
65	compared with unvaccinated persons (median age 73 years [Interquartile Range (IQR) 65-80] v. 59 years
66	[IQR 48-70]; p<0.001), more likely to have 3 or more underlying medical conditions (201 (70.8%) v. 2,305
67	(56.1%), respectively; p<0.001) and be residents of long-term care facilities [37 (14.5%) v. 146 (5.5%),
68	respectively; p<0.001]. From January 24 – July 24, 2021, cumulative hospitalization rates were 17 times
69	higher in unvaccinated persons compared with vaccinated persons (423 cases per 100,000 population v.
70	26 per 100,000 population, respectively); rate ratios were 23, 22 and 13 for those aged 18-49, 50-64,

- and ≥65 years respectively. For June 27 July 24, hospitalization rates were ≥10 times higher in
- 72 unvaccinated persons compared with vaccinated persons for all age groups across all weeks.
- 73 **Conclusion**: Population-based hospitalization rates show that unvaccinated adults aged ≥18 years are 17
- times more likely to be hospitalized compared with vaccinated adults. Rates are far higher in
- vinvaccinated persons in all adult age groups, including during a period when the Delta variant was the
- 76 predominant strain of the SARS-CoV-2 virus. Vaccines continue to play a critical role in preventing
- serious COVID-19 illness and remain highly effective in preventing COVID-19 hospitalizations.

#### 78 Introduction

As of August 21, 2021, 170 million people in the United States were fully vaccinated against COVID-19, 79 including >62% of the population aged  $\geq$ 18 years.<sup>2</sup> Consistent with other studies, data from the Centers 80 for Disease Control and Prevention's (CDC) Coronavirus Disease 2019-Associated Hospitalization 81 82 Surveillance Network (COVID-NET) have previously shown that all three vaccine products currently available are highly effective in preventing hospitalization in adults aged  $\geq 65$  years.<sup>3,4</sup> Infections in fully 83 vaccinated persons (i.e., vaccine breakthroughs cases) are expected,<sup>5</sup> even in the setting of highly 84 85 effective vaccines. While most infections occurring in fully vaccinated individuals have been mild or asymptomatic,<sup>5</sup> more serious SARS-CoV-2 infections can occur in fully vaccinated individuals.<sup>4</sup> However, 86 87 the characteristics of fully vaccinated patients hospitalized with COVID-19 and factors associated with 88 risk of vaccine breakthrough have not been well described. Using COVID-NET data representing >67,000 89 COVID-19-associated hospitalizations from January–June 2021, we compare characteristics of persons hospitalized with laboratory-confirmed SARS-CoV-2 virus infection by vaccination status and assess 90 91 characteristics of hospitalized cases with vaccination breakthrough. We also compare clinical outcomes 92 between unvaccinated and fully vaccinated persons admitted for COVID-19-associated illness. We use 93 state immunization information system (IIS) linked to both hospitalized cases with laboratory-confirmed 94 SARS-CoV-2 infection and the population of the defined COVID-NET catchment area to compare weekly 95 population-based hospitalization rates in vaccinated and unvaccinated individuals, including for late 96 June and July 2021, a period when the highly-transmissible Delta variant was the predominant strain circulating.<sup>6</sup> 97

98 Methods

## 99 COVID-NET description and data collected for all COVID-NET Cases

COVID-NET is a population-based surveillance system of laboratory-confirmed COVID-19-associated
hospitalizations comprising 99 counties in 14 states (California, Colorado, Connecticut, Georgia, Iowa,
Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah) and
covering approximately 10% of the US population. Hospitalized patients residing in a surveillance
catchment area with a positive molecular or rapid antigen detection test for SARS-CoV-2 during
hospitalization or within 14 days before admission are included as COVID-NET cases.<sup>7</sup> One site (Iowa)
does not have access to the state IISs and was excluded from this analysis.

107 Basic demographic information, including age, race and Hispanic ethnicity, sex, hospital admission date,

and evidence of a positive SARS-CoV-2 test are transmitted weekly on all patients.<sup>7</sup> Since few children

109 were fully vaccinated during the analysis period, this analysis was limited to adult cases aged  $\geq$ 18 years.

# 110 COVID-NET Sampling/Weighting Methodology

111 Detailed data on patient demographics, COVID-19 vaccination status, primary reason for admission,

select underlying medical conditions, and clinical outcomes, including ICU admission and death, are

113 collected on a representative sample of patients stratified by age and site. To select sampled cases,

random numbers are generated and assigned to each case. Sampling weights are based on the

probability of selection and adjusted for non-response; sample sizes vary by surveillance month, site and

age group and are based on the total number of cases identified in each of these strata.<sup>8</sup> Monthly

demographic and clinical data through June 2021 were the most recent data available at the time of thisstudy.

### 119 Vaccination definitions, weighting of cases with known vaccination status

120 Fully vaccinated cases were defined as having a positive SARS-CoV-2 test ≥14 days after either the

second dose of a 2-dose series or after one dose of a single dose series. Partial vaccination was defined

122	as ≥14 days after a single dose through <14 days after the second dose in a 2-dose series. If the SARS-
123	CoV-2 test date was not available, hospital admission date was used. Partially vaccinated patients and
124	patients with positive tests <14 days after one vaccine dose, regardless of type, were excluded from
125	further analyses.
126	Vaccination status for both hospitalized cases and the underlying population was determined by state IIS
127	data, as previously described. <sup>3</sup> We collected COVID-19 vaccination status (doses, dates administered,
128	and product) from state IISs for all sampled COVID-NET cases. Some sites expanded collection of
129	vaccination status to non-sampled cases, which were included for analysis of demographic factors and
130	population-based rates associated with vaccination if all cases in a single month and age group had
131	vaccination status available ("vaccine sample").
132	For fully vaccinated sampled cases only, COVID-NET personnel reviewed state health department
133	electronic laboratory records and other data sources for a positive SARS-CoV-2 tests predating the test
134	associated with the current hospitalization. This was done to exclude those who were reinfected or had
135	prolonged viral shedding from a prior SARS-CoV-2 infection that predated full vaccination and,
136	therefore, did not meet the definition of vaccine breakthrough (Supplementary Table 2). Data on prior
137	positive SARS-CoV-2 tests were not available for unvaccinated persons.
138	Comparison of Clinical Characteristics and Outcomes among a Weighted Sample of Fully
139	Vaccinated and Unvaccinated Hospitalized Cases with COVID-19
140	For all sampled cases, trained surveillance staff conduct medical chart abstractions using a standard case
141	report form. We compared demographic information, underlying medical conditions, clinical outcomes,

- signs and symptoms at admission, and reasons for admission between unvaccinated and fully vaccinated
- sampled cases ("comparison sample"). Underlying medical conditions were categorized into major
- 144 groups (Supplementary Table 1). Two physicians reviewed reason for admission and symptoms, and

145	those cases whose reason for admission might not have been primarily related to COVID-19, despite
146	receiving a positive SARS-CoV-2 laboratory test, were excluded from the comparison sample. $^3$
147	We used multivariable logistic regression to examine factors associated with vaccine breakthrough
148	cases; models included age, race and Hispanic ethnicity, long-term care facility (LTCF) residence, and
149	underlying medical conditions. We also used multivariable logistic regression to examine the association
150	of vaccination with severe COVID-19, defined as ICU admission or in-hospital death. Because older
151	adults were eligible for vaccination earlier than other age groups <sup>9</sup> and older age has been associated
152	with increased risk of vaccine breakthrough with other infections, we stratified all models, analyzing
153	those aged <65 and $\geq$ 65 years separately.
154	Description of Population-Based COVID-19-Associated Hospitalization Rates among Unvaccinated and
155	Vaccinated Persons
156	We collected a minimum set of data on all identified cases to produce weekly hospitalization rates
157	( <u>https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html)</u> for all COVID-NET cases. Incidence rates were
158	calculated using the National Center for Health Statistics' vintage 2019 bridge-race postcensal
159	population estimates for the counties included in COVID-NET surveillance. <sup>10</sup> To determine population-
160	based rates of hospitalization by vaccination status per 100,000 persons ≥18 years of age, county-level
161	coverage in the COVID-NET catchment area was estimated using population denominators. Vaccination
162	status was classified as described above for hospitalized cases using the vaccine sample; weekly
163	population-based rates were calculated based on denominators that changed weekly depending on the
164	vaccination status of individuals in the underlying population. Rate ratios were calculated for all fully
165	vaccinated and unvaccinated cases who met the case definition, regardless of prior SARS-CoV-2 test
166	results or reason for admission; overall rates for those ≥18 years were standardized to the underlying

hospitalization rates in unvaccinated with vaccinated persons only, data through the week ending July
24, 2021 were included, as they were the most recent data available at the time of this study. Weeks in
which the Delta variant was estimated to cause >50% of new SARS-COV-2 infections, June 27 – July 24,
2021,<sup>6</sup> were examined. A method for formally calculating vaccine effectiveness from COVID-NET data
has been published;<sup>11</sup> VE estimates will be included in a forthcoming manuscript.

#### 173 Statistical Analysis

174 Data from all cases aged ≥18 years and hospitalized with laboratory-confirmed COVID-19 during January 175 1-June 30, 2021 with linked vaccine registry data were used to describe the vaccination status of 176 hospitalized cases by age, sex, race and Hispanic ethnicity, and month of admission. The comparison 177 sample used in multivariable models included age groups (18–49, 50–64, ≥65 years), sex, and race and 178 ethnicity; models incorporated clustering by site to account for geographic differences. Other variables 179 with p-values <0.10 in bivariate analyses were included in the multivariable analyses. Model fit was 180 assessed with Quasi-likelihood under Independence Model Criterion (QIC). Log-linked Poisson 181 generalized estimating equations regression with an independent working correlation structure was 182 used to generate adjusted risk ratios (aRR) and 95% confidence intervals (CI). Data were analyzed using 183 SAS survey procedures to account for sampling weights. Unweighted case counts and weighted percentages are presented unless otherwise noted. Proportions by month with 95% confidence intervals 184 185 are presented for binary measures, and medians with interquartile ranges for continuous measures. We 186 used Taylor series linearization methods for variance estimation. All analyses were conducted using SAS 187 9.4 software (SAS Institute Inc., Cary, NC).

This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC
policy (see e.g., 45 C.F.R. part 46.102(I)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C.

190 Results

191	During January 1–June 30, 2021, there were 67,311 laboratory-confirmed COVID-19-associated
192	hospitalized cases ≥18 years identified in COVID-NET and meeting the case definition, among whom a
193	representative sample of 35,846 had vaccination data linked to state vaccination registries (vaccine
194	sample) (Supplementary Figure 1). Among these, 30,967 (87.6% (weighted percentages shown
195	throughout)) were unvaccinated, 1,791 (5.0%) had received 1 dose <14 d prior to admission, 1,753
196	(4.4%) were partially vaccinated and 1,255 (3%) were fully vaccinated ( <b>Table 1).</b> The number of cases
197	that were fully vaccinated increased from 1 (0.0%) in January to 321 (16.1%) in June. A greater
198	proportion of cases in older age groups were fully vaccinated; 32% of hospitalized cases aged ≥65 years
199	in June were fully vaccinated (Supplementary Figure 2).
200	Among a representative sample of 6,115 hospitalized adults aged $\geq$ 18 years, the following were
201	excluded (unweighted percentages shown for excluded cases): 282 (4.6%) who had received one dose of
202	vaccine <14 days prior to the positive SARS-CoV-2 test, 286 (4.7%) who were partially vaccinated, 14
203	(0.2%) with unknown vaccination status, and 33 (0.5%) cases with incomplete data. Among remaining
204	the cases (n=5,550), 390 were fully vaccinated and 5,160 were unvaccinated; among fully vaccinated
205	cases, 52/390 (13%) had evidence of prior SARS-CoV-2 positive tests and were also excluded. An
206	additional 716 (13%) of the remaining 5,448 cases were excluded as their reason for admission might
207	not have been primarily related to COVID-19; the proportion of cases excluded for this reason was
208	similar among the remaining vaccinated cases compared with unvaccinated cases ((46/338 (14%) v.
209	670/5110 (13%), respectively; p-value = 0.79)). <b>(Supplementary Figure 1).</b>
210	The comparison sample was thus restricted to the remaining 4,732 cases with hospitalization associated
211	primarily with COVID-19 illness, including 4,440 unvaccinated and 292 fully vaccinated cases (Table 2).
212	Among fully vaccinated cases, the median time from full vaccination status until hospital admission was
213	42 days (IQR 28–68). Among all adults aged ≥18 years, fully vaccinated cases were older when compared
214	to unvaccinated cases [median age 73 years (IQR 65-80) v. 59 years (IQR 48-70); p<0.001] and more

215 likely to be LTCF residents [37 (14.5%) v. 146 (5.5%), respectively; p<0.001]. In addition, 69 (32.1%) fully 216 vaccinated cases were more likely to be immunosuppressed compared with 442 (11.3%) unvaccinated 217 cases (p<0.001); these fully vaccinated immunosuppressed cases included 25 (36%) and 14 (20%) cases 218 with solid organ malignancy and a history of a solid organ transplant, respectively. Vaccinated cases 219 were also more likely to have 3 or more underlying medical conditions compared with unvaccinated 220 cases (201 (70.8%) v. 2,305 (56.1%), respectively; p<0.001). 221 On multivariable analysis, after adjusting for, age, sex, race and Hispanic ethnicity, LTCF status, and 222 underlying medical conditions, and excluding those whose reason for hospitalization was likely not 223 primarily COVID-19-related, fully vaccinated patients aged ≥65 years, were more likely to be

immunosuppressed (aRR: 3.2 (95% Cl 2.0-5.1) and to be obese (aRR: 1.6 (95% Cl 1.0-2.5) than

225 unvaccinated patients (Figure 1B). Fully vaccinated patients aged <65 years were more likely to have

underlying neurologic and gastrointestinal/liver diseases (aRRs: 1.6 (95% Cl 1.0-2.6) and 2.3 (95% Cl 1.0-

5.4), respectively).

228 The number and proportion of fully vaccinated persons admitted to the ICU was similar to unvaccinated 229 persons (60 (20.6%) v. 931 (20.0%), respectively; p-value=0.66), as were results for in-hospital death (23 230 (7.5%) v. 342 (8.4%), respectively; p-value=0.69). Median length of stay was significantly longer in fully 231 vaccinated persons (median 5 days (IQR 3–8) v. 4 days (IQR 2–9), respectively; p<0.001) (Table 2). On 232 multivariable analysis adjusting for age, sex, race, and underlying medical conditions, being fully 233 vaccinated was significantly associated with reduced risk of severe disease (i.e. ICU admission and/or 234 death) in those aged <65 years (aRR 0.8 (95% Cl 0.6–1.0), but this association was not significant in those 235 aged  $\geq$ 65 years (aRR 1.1 (95% Cl 0.7–1.6) (**Supplementary Tables 3A-B**).

236 **Population-based rates of COVID-19-associated hospitalization by vaccination status** 

237	During the study period, the percentage of persons aged $\geq$ 18 years in the COVID-NET catchment area
238	who were fully vaccinated increased from 0.9% in January to 57% in June 2021. The COVID-NET
239	catchment population that was fully vaccinated varied by week and age group (Supplementary Figure
240	<b>3A–D)</b> . From January 24–July 24, 2021, the age-adjusted cumulative hospitalization rate among persons
241	≥18 years of age was 432 hospitalized cases per 100,000 unvaccinated persons compared with 26 per
242	100,000 fully vaccinated persons, a 17-fold higher cumulative rate (Figure 2A); cumulative rate ratios
243	were 26, 22 and 13 for those aged 18–49, 50–64, and ≥65 years respectively ( <b>Supplementary Table 4).</b>
244	The weekly overall COVID-NET hospitalization rates tracked closely with the hospitalization rates of the
245	unvaccinated population earlier in the study period, but as vaccination coverage increased, the overall
246	rate started to converge with the rate in the fully vaccinated population (Figure 2B, Figure 3A-C). The
247	weekly rate ratio varied each week with no clear pattern (range in those aged ≥18 years: 6–31). For June
248	27–July 24, hospitalization rates were ≥10 times higher in unvaccinated persons compared with
249	vaccinated persons for all age groups across all weeks (rate ratio range in those aged $\geq$ 18 years: 12-19)
250	(Supplementary Table 4).
251	Discussion
252	In this analysis using data from a representative sample of over 67,000 laboratory-confirmed COVID-19-
253	associated hospitalizations in persons aged ≥18 years, we demonstrated that cumulative population-
254	based rates of COVID-19-associated hospitalization were approximately 17 times higher in unvaccinated
255	persons compared with vaccinated persons, and more than 13 times higher in adults aged ≥65 years.
256	Rates remained ≥10 times higher in unvaccinated persons compared with vaccinated persons in all adult
257	age groups across all weeks in late June and July 2021, a period in which the Delta variant has
258	predominated, suggesting that vaccines remain highly effective in preventing hospitalizations in all adult

- age groups. Those persons who were hospitalized despite being fully vaccinated were more medically
- 260 fragile at baseline than those who were unvaccinated. Fully vaccinated cases were older, more likely to

reside in LCTFs, and had more underlying medical conditions; nearly a third (32%) had

immunosuppressive conditions, compared with 11% of those who were unvaccinated.

Our finding that a substantial and growing proportion of hospitalized persons were fully vaccinated is not surprising; the proportion of hospitalized cases who are fully vaccinated is expected to increase as population vaccination coverage increases. Given the high vaccination coverage, particularly in older age groups, which was more than 80% in July for those ≥65 years,<sup>2</sup> the finding that 16% of hospitalized cases ≥18 years during that month were fully vaccinated is consistent with what we would expect from highly effective vaccines.

269 This analysis demonstrated that population-based rates of hospitalization were consistently far higher in 270 unvaccinated persons compared with fully vaccinated persons in all age groups and over time. Using 271 detailed IIS data from of a defined population, a 17-times greater cumulative hospitalization rate in 272 unvaccinated persons is consistent with ongoing high levels of vaccine effectiveness in preventing 273 hospitalizations and suggests that increasing vaccination coverage can prevent serious illness and death. 274 Some of the differences in hospitalization rates between the unvaccinated and vaccinated populations 275 may be attributable in part to differences in mask-wearing and physical distancing between the two 276 groups. Cumulative rate ratios were lower in older adults than younger groups, but vaccinated adults 277 aged  $\geq$ 65 years had hospitalization rates that were more than 90% lower than unvaccinated persons in 278 the same age group; recent increases in hospitalization rates appear to be driven disproportionately by 279 unvaccinated persons. Far higher rates of hospitalization among unvaccinated persons compared to 280 vaccinated persons of all ages persisted in July 2021, a time when the highly-transmissible Delta variant was the predominant variant circulating<sup>6</sup> and hospitalization rates among vaccinated individuals 281 282 remained comparatively low and stable. Although studies have suggested that current vaccines may be 283 less effective in preventing SARS-CoV-2 infections due to the Delta variant compared than with

previously circulating varians,<sup>12-14</sup> this analysis suggests that vaccination remains highly effective against
 the Delta variant in preventing severe disease resulting in hospitalization.<sup>6</sup>

286 We demonstrated that, consistent with other studies, among hospitalized cases, vaccinated persons 287 reflected older and more medically fragile populations that were prioritized to receive the vaccine early. 288 Those aged  $\geq$ 75 years, LTCF residents, those who are immunocompromised or have multiple underlying 289 conditions may be among the most vulnerable to severe infection and the least likely to mount an 290 adequate immune response to immunization; given early receipt of the vaccine, these populations may also be vulnerable to any potential waning of effectiveness over time.<sup>4,15,16</sup> Increased vulnerability to 291 292 severe disease resulting in hospitalization, even if fully vaccinated, supports the importance of 293 vaccination among LCTF staff and visitors in protecting persons vulnerable to severe COVID-19. The high 294 proportion of fully vaccinated patients who were immunocompromised also supports the recent 295 recommendation for a third vaccine dose for immunocompromised adults who had previously received 296 mRNA vaccines, although more research is needed to understand the extent to which an additional dose of vaccine results in increased protection in immunocompromised individuals.<sup>17</sup> 297 298 In the outpatient setting, vaccination likely attenuates disease severity if a breakthrough infection occurs,<sup>5</sup> but our analysis showed that conditional on being hospitalized, vaccinated persons were still at 299 300 a high risk of severe outcomes, with more than 20% admitted to the ICU. We did not find any clear 301 difference in the risk for ICU admission or in-hospital death between vaccinated and unvaccinated 302 persons. This may reflect the fact that those who were hospitalized despite vaccination may be more 303 vulnerable to severe infection at baseline than those who are not vaccinated. In addition, unidentified 304 confounders that are not well-accounted for may affect these results; further detailed analyses 305 examining clinical presentation and outcomes are planned.

306	This analysis has several limitations. Although COVID-NET covers approximately 10% of the U.S.
307	population, our findings may not be generalizable to the entire country. Since SARS-CoV-2 testing was
308	conducted at the discretion of healthcare professionals, COVID-NET may not have captured all COVID-
309	19-associated hospitalizations. The primary reason for hospital admission was not always clear, and
310	some patients who met the COVID-NET case definition may have been hospitalized for reasons that
311	were not primarily related to COVID-19. The inclusion of these hospitalizations in rate calculations could
312	have resulted in an overestimation of hospitalization rates for COVID-19 for both unvaccinated and
313	vaccinated persons.
314	Using population-based hospitalization rates, our study found unvaccinated adults are hospitalized at
315	rates that are 17 times higher than for vaccinated adults in the same catchment areas. Rates of COVID-
316	19-associated hospitalizations are far higher in unvaccinated persons in all adult age groups, even during
317	a period when the highly-transmissible Delta variant was the predominant circulating variant. <sup>12</sup>
318	Population-based hospitalization rates will be a critical metric in the continued assessment of the
319	effectiveness of vaccines in the population, and complementary to vaccine effectiveness studies using
320	other methods. <sup>4,18</sup> The much higher rates observed in unvaccinated persons compared to vaccinated
321	adults suggest that vaccines remain highly effective in preventing hospitalization for COVID-19 illness.
322	Continuing to increase vaccination coverage in all eligible groups is crucial to preventing severe COVID-
323	19.

325 Funding: This work was supported by the Centers of Disease Control and Prevention through an 326 Emerging Infections Program cooperative agreement (grant CK17-1701) and through a Council of State 327 and Territorial Epidemiologists cooperative agreement (grant NU380T000297-02-00). 328 Acknowledgments: Roxanne Archer, Susan Brooks, Monica Napoles, Jeremy Roland, Tiffany Tsukuda, CA 329 Emerging Infections Program; Arthur Reingold, University of California, Berkeley; Rachel Herlihy, 330 Breanna Kawasaki, Colorado Department of Public Health and Environment; Ann Basting, Tessa Carter, 331 Maria Correa, Daewi Kim, Carol Lyons, Amber Maslar, Julie Plano, Connecticut Emerging Infections 332 Program, Yale School of Public Health; Katelyn Ward, Georgia Emerging Infections Program, Georgia 333 Department of Health, Division of Infectious Diseases, School of Medicine, Emory University; Marina 334 Bruck, Rayna Ceasar, Gracie Chambers, Taylor Eisenstein, Emily Fawcett, Asmith Joseph, Grayson Kallas, 335 Stephanie Lehman, Jana Manning, Annabel Patterson, Allison Roebling, Chandler Surell, Georgia 336 Emerging Infections Program, Georgia Department of Health, Veterans Affairs Medical Center, 337 Foundation for Atlanta Veterans Education and Research; David Blythe, Alicia Brooks, Elisabeth Vaeth, 338 Cindy Zerrlaut, Maryland Department of Health; Rachel Park, Michelle Wilson, Maryland Emerging 339 Infections Program - The Johns Hopkins Bloomberg School of Public Health; Chloe Brown, Jim Collins, 340 Justin Henderson, Shannon Johnson, Sue Kim, Lauren Leegwater, Sierra Peguies-Khan, Val Tellez Nunez, 341 Michigan Department of Health and Human Services; Aaron Bieringer, Erica Bye, Richard Danila, Kristen 342 Ehresmann, Corinne Holtzman, Sydney Kuramoto, Stephanie Meyer, Miriam Muscoplat, Rachel 343 Ostadkar, Minnesota Department of Health; Marianne Murphy, Murtada Khalifa, Yassir Talha, CDC 344 Foundation/New Mexico Department of Health; Melissa Judson, Sunshine Martinez, Jasmyn Sanchez, 345 Chad Smelser, Daniel Sosin, New Mexico Department of Health; Kathy M. Angeles, Melissa Christian, 346 Nancy Eisenberg, Emily B. Hancock, Sarah A. Khanlian, Sarah Lathrop, Wickliffe Omondi, Mayvilynne 347 Poblete, Dominic Rudin, Yadira Salazar-Sanchez, Sarah Shrum Davis, Chelsea McMullen,

348	Susan Ropp, New Mexico Emerging Infections Program; Kerianne Engesser, Suzanne McGuire, Adam
349	Rowe, Nancy Spina, New York State Department of Health; Nancy Bennett, Virginia Cafferky, Maria
350	Gaitan, Christine Long, Thomas Peer, Kevin Popham, University of Rochester School of Medicine and
351	Dentistry; Kylie Seeley, Oregon Health & Science University School of Medicine; Ama Owusu-Dommey,
352	Emily Youngers, Breanna McArdle, Public Health Division; Oregon Health Authority; Kathy Billings,
353	Katie Dyer, Anise Elie, Karen Leib, Tiffanie Markus, Terri McMinn, Danielle Ndi, Manideepthi
354	Pemmaraju, John Ujwok, Vanderbilt University Medical Center; Ian Buchta, Amanda Carter,
355	Ryan Chatelain, Andrew Haraghey, Laine McCullough, Jacob Ortega, Andrea Price, Tyler Riedesel,
356	llene Risk, Caitlin Shaw, Melanie Spencer, Ashley Swain, Salt Lake County Health Department;
357	Keegan McCaffrey, Utah Department of Health; Kelly Oakeson, Alessandro Rossi, Utah Public Health

358 Laboratory

## 360 References

361	1.	Garg S, Patel K, Pham H, et al. Clinical Trends Among U.S. Adults Hospitalized with COVID-19,
362		March-December 2020. medRxiv 2021:2021.04.21.21255473. DOI:
363		10.1101/2021.04.21.21255473.
364	2.	CDC COVID Data Tracker. Centers for Diseases Control and Prevention.
365		(https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total).
366	3.	Moline HL, Whitaker M, Deng L, et al. Effectiveness of COVID-19 Vaccines in Preventing
367		Hospitalization Among Adults Aged >/=65 Years - COVID-NET, 13 States, February-April 2021.
368		MMWR Morbidity and mortality weekly report 2021;70(32):1088-1093. DOI:
369		10.15585/mmwr.mm7032e3.
370	4.	Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for
371		Preventing Covid-19 Hospitalizations in the United States. Clinical infectious diseases : an official
372		publication of the Infectious Diseases Society of America 2021. DOI: 10.1093/cid/ciab687.
373	5.	Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19 with the
374		BNT162b2 and mRNA-1273 Vaccines. The New England journal of medicine 2021;385(4):320-
375		329. DOI: 10.1056/NEJMoa2107058.
376	6.	CDC Data Tracker: Variant Proportions. Centers for Disease Control and Prevention.
377		(https://covid.cdc.gov/covid-data-tracker/#variant-proportions).
378	7.	Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients
379		Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States,
380		March 1-30, 2020. MMWR Morbidity and mortality weekly report 2020;69(15):458-464. DOI:
381		10.15585/mmwr.mm6915e3.
382	8.	Garg S, Patel K, Pham H, et al. Clinical Trends Among U.S. Adults Hospitalized With COVID-19,
383		March to December 2020 : A Cross-Sectional Study. Annals of internal medicine 2021. DOI:
384		10.7326/M21-1991.
385	9.	McClung N, Chamberland M, Kinlaw K, et al. The Advisory Committee on Immunization
386		Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine - United States,
387		2020. MMWR Morbidity and mortality weekly report 2020;69(47):1782-1786. DOI:
388		10.15585/mmwr.mm6947e3.
389	10.	U.S. Census Populations With Bridged Race Categories
390		(https://www.cdc.gov/nchs/nvss/bridged_race.htm).
391	11.	Tenforde MW, Olson SM, Self WH, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines
392		Against COVID-19 Among Hospitalized Adults Aged >/=65 Years - United States, January-March
393		2021. MMWR Morbidity and mortality weekly report 2021;70(18):674-679. DOI:
394		10.15585/mmwr.mm7018e1.
395	12.	Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the
396		B.1.617.2 (Delta) Variant. The New England journal of medicine 2021. DOI:
397		10.1056/NEJMoa2108891
398	13.	S. Nanduri TP, G. Derado et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in
399		Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During
400		Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare
401		Safety Network, March 1–August 1, 2021. MMWR Morbidity and mortality weekly report 2021.
402	14.	Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for
403		COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv
404		2021:2021.08.06.21261707. DOI: 10.1101/2021.08.06.21261707.

405	15.	Dooling K, Marin M, Wallace M, et al. The Advisory Committee on Immunization Practices'
406		Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States,
407		December 2020. MMWR Morbidity and mortality weekly report 2021;69(5152):1657-1660. DOI:
408		10.15585/mmwr.mm695152e2.
409	16.	Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough:
410		clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clinical
411		microbiology and infection : the official publication of the European Society of Clinical
412		Microbiology and Infectious Diseases 2021. DOI: 10.1016/j.cmi.2021.06.036.
413	17.	Media Statement from CDC Director Rochelle P. Walensky, MD, MPH, on Signing the Advisory
414		Committee on Immunization Practices' Recommendation for an Additional Dose of an mRNA
415		COVID-19 Vaccine in Moderately to Severely Immunocompromised People. CDC.
416	18.	Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of
417		BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among
418		Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S.
419		Locations, December 2020-March 2021. MMWR Morbidity and mortality weekly report

420 2021;70(13):495-500. DOI: 10.15585/mmwr.mm7013e3.

#### Tables

Table 1. Demographics of a representative sample<sup>a</sup> of hospitalized adults ≥18 years with laboratory-confirmed COVID-19-associated hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States<sup>b</sup>

Table 2. Demographics, underlying conditions, reason for admission, and clinical outcomes among a representative sample of unvaccinated and fully vaccinated hospitalized adults aged  $\geq$ 18 years with laboratory-confirmed COVID-19-associated hospitalization admitted January 1– June 30, 2021, stratified by age (<65 and  $\geq$ 65 years) and restricted to those with COVID-19-associated hospitalization as the likely primary reason for admission — COVID-NET, 13 States<sup>a</sup>

#### Figures

Figure 1. Multivariable model<sup>a</sup> assessing factors associated with full vaccination status in hospitalized adults with laboratory-confirmed COVID-19-associated hospitalization admitted January 1–June 30, 2021, restricting to those with COVID-19-associated hospitalization as the likely primary reason for admission, among those aged A) <65 years and B) ≥65 years — COVID-NET, 13 States<sup>b</sup>

Figure 2. Age-adjusted population-based rates<sup>a</sup> of COVID-19-associated hospitalizations among unvaccinated and fully vaccinated adults ≥18 years of age admitted January 24–June 26, 2021, A) cumulative and B) by week of admission — COVID-NET, 13 States<sup>b</sup>

Figure 3. Age-specific population-based rates<sup>a</sup> of COVID-19-associated hospitalizations among unvaccinated and fully vaccinated adults ≥18 years of age admitted January 24–July 24, 2021, by week of admission and age A) 18–49 years B) 50–64 years and C) ≥65 years — COVID-NET, 13 States<sup>b</sup>

#### Supplementary material

Supplementary Table 1. Categorization of Underlying Medical Conditions

Supplementary Table 2. Characteristics of fully vaccinated cases who had a prior positive SARS-CoV-2 test compared with fully vaccinated cases with no evidence of prior infection, among adults  $\geq$  18 years admitted January 1–June 30, 2021 — COVID-NET, 13 States<sup>a</sup>

Supplementary Table 3A. Multivariable model<sup>a</sup> assessing factors associated with severe COVID-19 diseases (ICU, in-hospital death) in hospitalized adults with laboratory-confirmed COVID-19-associated hospitalization admitted January 1 – June 30, 2021, restricting to those with COVID-19-associated hospitalization as the likely primary reason for admission, among those aged <65 years — COVID-NET, 13 States<sup>b</sup>

Supplementary Table 3B. Multivariable model<sup>®</sup> assessing factors associated with severe COVID-19 diseases (ICU, in-hospital death) in hospitalized adults with laboratory-confirmed COVID-19-associated hospitalization admitted January 1–June 30, 2021, restricting to those with COVID-19-associated hospitalization as the likely primary reason for admission, among those aged ≥65 years — COVID-NET, 13 States<sup>b</sup>

Supplementary Table 4. Rate ratios of COVID-19-associated hospitalizations in unvaccinated vs vaccinated patients among all adults aged ≥18 years and by age group<sup>a</sup>, January 24–June 26, 2021 — COVID-NET, 13 States<sup>b</sup>

#### Supplementary Figures

Supplementary Figure 1. Selection of cases for analysis of adults ≥18 years with laboratory-confirmed COVID-19-associated hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States<sup>a</sup>

Supplementary Figure 2. Proportion of adults ≥18 years with COVID-19-associated hospitalizations admitted January 1 – June 30, 2021 who are fully vaccinated, by age group and month of admission — COVID-NET, 13 States

Supplementary Figure 3. COVID-NET catchment population by vaccination status and week, used as denominator in population-based-rate calculations<sup>a</sup> among A) all adults aged  $\geq$ 18 years, B) 18–49 years, C) 50–64 years, and D)  $\geq$ 65 years — COVID-NET, January 24–July 24, 2021

Tables

Table 1. Demographics of a representative sample<sup>a</sup> of hospitalized adults aged ≥18 years with laboratory-confirmed COVID-19-associated hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States<sup>b</sup>

Characteristics	Adults ≥18 years	Unvaccinated n (weighted %)	Vaccinated <14 days prior to positive test n (weighted %) <sup>c</sup>	Partially vaccinated <sup>d</sup> n (weighted %)	Fully vaccinated n (weighted %)
Total <sup>e</sup>	35,766	30,967 (87.6)	1,791 (5.0)	1,753 (4.4)	1,255 (3.0)
Age group (median, IQR)	60 (46–72)	58 (45–70)	69 (59–80)	71 (61–82)	72 (63–81)
18–49 years	10,979	10,342 (95.1)	285 (2.4)	197 (1.4)	155 (1.2)
50–64 years	10,407	9,265 (90.9)	507 (4.0)	396 (3.5)	239 (1.6)
65–74 years	6,686	5,573 (82.9)	401 (6.9)	400 (5.8)	312 (4.4)
75–84 years	4,788	3,692 (79.4)	343 (6.1)	428 (7.4)	325 (7.1)
≥85 years	2,906	2,095 (74.2)	255 (11.5)	332 (9.4)	224 (4.9)
Sex					
Male	17,737	15,357 (87.3)	895 (5.3)	866 (4.2)	619 (3.1)
Female	18,029	15,610 (87.8)	896 (4.8)	887 (4.5)	636 (3.0)
Race and Hispanic ethnicity <sup>f</sup>					
Black	8,099	7,277 (91.0)	349 (3.6)	319 (3.6)	154 (1.8)
White	16,355	13,594 (84.9)	916 (5.4)	1,019 (5.4)	826 (4.3)
Hispanic or Latino	6,253	5,691 (90.1)	251 (5.9)	187 (2.3)	124 (1.6)
American Indian/Alaska Native	355	309 (83.8)	8 (7.9)	18 (5.3)	20 (3.0)
Asian/Pacific Islander	1,967	1,690 (85.5)	128 (6.7)	96 (4.9)	53 (2.9)
Other/Unknown	2,385	2,096 (89.0)	116 (4.4)	101 (4.3)	72 (2.4)

Characteristics	Adults ≥18 years	Unvaccinated n (weighted %)	Vaccinated <14 days prior to positive test n (weighted %) <sup>c</sup>	Partially vaccinated <sup>d</sup> n (weighted %)	Fully vaccinated n (weighted %)
Month of admission					
January	9,136	8,648 (93.9)	347 (4.7)	140 (1.3)	1 (0.0)
February	7,549	6,682 (89.0)	383 (4.1)	437 (6.3)	47 (0.6)
March	5,899	4,963 (85.2)	385 (6.0)	382 (5.7)	169 (3.1)
April	6,468	5,232 (82.0)	452 (6.7)	469 (6.7)	315 (4.6)
Мау	4,673	3,855 (81.5)	179 (4.2)	237 (5.3)	402 (9.0)
June	2,041	1,587 (76.6)	45 (2.5)	88 (4.9)	321 (16.1)

Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19–Associated Hospitalization Surveillance Network; IQR = interquartile range. <sup>a</sup>Percentages are weighted and represent row percentages

<sup>b</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

<sup>c</sup>This group is excluded from further analyses.

<sup>d</sup>Received one dose of two-dose series (for Pfizer/BioNTech and Moderna). This group is excluded from further analyses.

<sup>e</sup>80 additional cases were excluded from all analyses due to unknown vaccination status

<sup>f</sup>Race and Hispanic ethnicity: Data on race and ethnicity were categorized as follows: non-Hispanic White (White), non-Hispanic Black (Black), non-Hispanic Asian or Pacific Islander (Asian/Pacific Islander), non-Hispanic American Indian or Alaska Native (American Indian/Alaska Native) and Other/Unknown. If ethnicity was unknown (8% of cases), non-Hispanic ethnicity was assumed. Table 2. Demographics, underlying conditions, reason for admission, and clinical outcomes among a representative sample of unvaccinated and fully vaccinated hospitalized adults aged  $\geq$ 18 years with laboratory-confirmed COVID-19-associated hospitalization admitted January 1– June 30, 2021, stratified by age (<65 and  $\geq$ 65 years) and restricted to those with COVID-19-associated hospitalization as the likely primary reason for admission — COVID-NET, 13 States<sup>a</sup>

	Adults ≥18 years				<65 years			≥65 years			
Category	Total	Unvaccinated	Fully	p-value <sup>b</sup> Total	Unvaccinated	Fully	p-value <sup>b</sup>	Total	Unvaccinated	Fully	p-value <sup>b</sup>
		n (weighted	vaccinated		n (weighted %)	vaccinated			n (weighted %)	vaccinated	
		%)	n			n				n	
			(weighted			(weighted				(weighted	
			%)			%)				%)	
Total	4,732	4,440 (97.1)	292 (2.9)	3,131	3,039 (98.7)	92 (1.3)		1,601	1,401 (94.8)	200 (5.2)	
Age group (median, IQR)	59	59 (48–70)	73 (65–80)	<.001 51	51 (42–58)	52 (36–60)	0.15	73	73 (65–101)	77 (65–99)	0.70
	(48-	-		(42–				(65–	-		
	70)			58)				101)			
18–49 years	1,428	1,399 (26.3)	29 (8.7)	1,428	1,399 (44.5)	29 (34.9)					
50–64 years	1,703	1,640 (32.9)	63 (16.3)	1,703	1,640 (55.5)	63 (65.1)					
≥65 years	1,601	1,401 (40.8)	200 (75.0)					1,601	. 1,401 (100.0)	200 (100.0)	
Sex				0.63			0.32				0.70
Male	2,420	2,275 (51.6)	145 (49.3)	1,616	1,576 (50.3)	40 (43.7)		804	699 (53.5)	105 (51.1)	
Female	2,312	2,165 (48.4)	147 (50.7)	1,515	1,463 (49.7)	52 (56.3)		797	702 (46.5)	95 (48.9)	
Race and Hispanic				<.001			<.001				0.34
ethnicity <sup>c</sup>											
White	2,467	2,263 (45.9)	204 (66.3)	1,407	1,347 (37.9)	60 (61.7)		1,060	916 (57.4)	144 (67.8)	
Black	1,058	1,023 (29.3)	35 (17.5)	796	785 (33.4)	11 (14.8)		262	238 (23.4)	24 (18.5)	

		Adults	≥18 years			<65	years		≥65 years			
Category	Total	Unvaccinated n (weighted	Fully vaccinated	p-value <sup>b</sup>	Total	Unvaccinated n (weighted %)	Fully vaccinated	p-value <sup>b</sup>	Total	Unvaccinated n (weighted %)	Fully vaccinated	p-value <sup>b</sup>
		%)	n (weighted %)				n (weighted %)				n (weighted %)	
Hispanic or Latino	731	. 701 (13.4)	30 (9.0)		597	581 (17.1)	16 (18.6)		134	120 (8.2)	14 (5.7)	
Other/Unknown <sup>d</sup>	476	453 (11.4)	23 (7.2)		331	326 (11.7)	5 (4.9)		145	127 (11.0)	18 (8.0)	
Month of admission				<.001				<.001				<.001
January	852	851 (39.0)	1 (0.6)		545	544 (31.8)	1 (2.3)		307	307 (49.5)	0 (0.0)	
February	739	737 (16.4)	2 (1.5)		490	490 (14.9)	0 0.0)		249	247 (18.6)	2 (2.1)	
March	719	701 (14.3)	18 (13.0)		531	527 (16.0)	4 (7.0)		188	174 (11.7)	14 (15.0)	
April	713	674 (17.6)	39 (34.2)		472	464 (22.0)	8 (19.8)		241	210 (11.3)	31 (39.0)	
Мау	924	825 (9.4)	99 (31.2)		602	568 (11.3)	34 (41.8)		322	257 (6.7)	65 (27.7)	
June	785	652 (3.3)	133 (19.3)		491	446 (4.1)	45 (29.0)		294	206 (2.2)	88 (16.1)	
Code status on admission				<.001				0.51				0.17
Full code	4,010	3,788 (84.8)	222 (74.5)		2,815	2,735 (91.3)	80 (87.4)		1,195	1,053 (75.5)	142 (70.3)	
DNR/DNI/CMO	303	256 (6.3)	47 (17.3)		49	47 (1.2)	2 (2.7)		254	209 (13.7)	45 (22.1)	
Unknown	419	396 (8.8)	23 (8.2)		267	257 (7.5)	10 (10.0)		152	139 (10.8)	13 (7.6)	
LTCF residence <sup>e</sup>	183	146 (5.5)	37 (14.5)	<.001	49	44 (1.8)	5 (5.0)	0.06	134	102 (10.9)	32 (17.7)	0.09
Any underlying medical condition	4,319	4,040 (92.0)	279 (96.4)	0.02	2,785	2,701 (89.1)	84 (89.4)	0.95	1,534	1,339 (96.2)	195 (98.7)	0.04
Hypertension	2,600	2,398 (59.9)	202 (70.5)	0.02	1,389	1,342 (46.4)	47 (52.7)	0.34	1,211	1,056 (79.6)	155 (76.5)	0.53

		Adults	s≥18 years			<65	years		≥65 years			
Category	Total	Unvaccinated	Fully	p-value <sup>b</sup>	Total	Unvaccinated	Fully	p-value <sup>b</sup>	Total	Unvaccinated	Fully	p-value <sup>b</sup>
		n (weighted %)	n (weighted %)			n (weigntea %)	vaccinated n (weighted %)			n (weighted %)	n (weighted %)	
Obesity <sup>f</sup>	2,429	2,308 (49.9)	121 (48.4)	0.76	1,815	1,769 (58.2)	46 (50.0)	0.21	614	539 (37.8)	75 (47.9)	0.10
Chronic metabolic disease	1,907	1,765 (43.5)	142 (48.5)	0.29	1,117	1,083 (37.2)	34 (42.6)	0.41	790	682 (52.6)	108 (50.5)	0.73
Diabetes mellitus	1,526	1,420 (36.1)	106 (38.1)	0.66	906	877 (30.2)	29 (38.9)	0.17	620	543 (44.6)	77 (37.8)	0.26
Chronic lung disease	1,458	1,352 (30.5)	106 (39.2)	0.06	910	875 (30.1)	35 (40.8)	0.08	548	477 (31.1)	71 (38.6)	0.12
Asthma/Reactive airway disease	683	637 (13.7)	46 (18.7)	0.15	493	472 (15.5)	21 (23.9)	0.08	190	165 (11.1)	25 (16.9)	0.17
COPD	435	392 (9.8)	43 (14.2)	0.13	191	180 (6.6)	11 (10.2)	0.28	244	212 (14.5)	32 (15.6)	0.80
Cardiovascular disease <sup>g</sup>	1,504	1,347 (35.6)	157 (58.6)	<.001	635	606 (20.7)	29 (31.7)	0.04	869	741 (57.3)	128 (67.5)	0.07
Heart failure	456	399 (12.8)	57 (24.6)	0.003	187	180 (7.5)	7 (5.3)	0.37	269	219 (20.4)	50 (31.1)	0.07
Coronary artery disease	520	462 (13.0)	58 (18.6)	0.09	159	155 (5.5)	4 (6.2)	0.85	361	. 307 (23.8)	54 (22.7)	0.84
Neurologic disease	743	661 (17.2)	82 (33.0)	<.001	345	327 (10.5)	18 (22.9)	0.004	398	334 (27.0)	64 (36.4)	0.09
Renal disease	673	584 (16.5)	89 (30.4)	<.001	274	259 (10.3)	15 (18.2)	0.05	399	325 (25.4)	74 (34.5)	0.10
Immunosuppressive condition	511	442 (11.3)	69 (32.1)	<.001	297	275 (10.1)	22 (23.8)	<.001	214	167 (13.2)	47 (34.9)	<.001
Solid organ malignancy	177	152 (3.8)	25 (13.7)	<.001	80	72 (2.6)	8 (8.6)	0.007	97	80 (5.6)	17 (15.4)	0.005
Transplant	59	45 (1.8)	14 (5.5)	0.004	41	33 (1.9)	8 (9.5)	<.001	18	12 (1.8)	6 (4.2)	0.19
Gastrointestinal or liver	289	265 (5.6)	24 (7.3)	0.35	192	181 (5.1)	11 (15.0)	0.001	97	84 (6.3)	13 (4.8)	0.53

		Adults	s≥18 years			<65	5 years			≥65 y	ears	
Category	Total	Unvaccinated n (weighted %)	Fully vaccinated n (weighted %)	p-value <sup>b</sup>	Total	Unvaccinated n (weighted %)	Fully vaccinated n (weighted %)	p-value <sup>b</sup>	Total	Unvaccinated n (weighted %)	Fully vaccinated n (weighted %)	p-value <sup>t</sup>
disease							,,,					
Blood disorder	164	· 145 (2.9)	19 (5.4)	0.03	95	90 (2.2)	5 (6.1)	0.03	69	55 (3.9)	14 (5.2)	0.46
Rheumatologic or autoimmune disease	174	150 (3.5)	24 (8.7)	0.01	94	91 (3.2)	3 (4.3)	0.63	80	59 (3.9)	21 (10.1)	0.02
Number of underlying conditions <sup>h</sup>				<.001				0.12				0.27
0	444	431 (8.6)	13 (3.6)		377	369 (11.9)	8 (10.6)		67	62 (3.8)	5 (1.3)	
1	735	711 (14.3)	24 (6.3)		578	565 (18.3)	13 (10.8)		157	146 (8.5)	11 (4.8)	
2	1,047	993 (21.0)	54 (19.3)		760	737 (23.2)	23 (19.1)		287	256 (17.7)	31 (19.3)	
≥3	2,506	6 2,305 (56.1)	201 (70.8)		1,416	1,368 (46.5)	48 (59.4)		1,090	937 (70.0)	153 (74.6)	
Outcomes												
ICU admission	991	. 931 (20.0)	60 (21.6)	0.66	646	627 (19.2)	19 (17.7)	0.75	345	304 (21.2)	41 (22.9)	0.72
In-hospital death	365	342 (8.4)	23 (7.5)	0.69	168	165 (5.7)	3 (3.2)	0.36	197	/ 177 (12.3)	20 (9.0)	0.30
Median length of stay in days (IQR)		4 (2–9)	5 (3–8)	<.001		4 (2-7)	4 (2–6)	<.001		6 (3–11)	5 (3–9)	<.001

Abbreviations: BIPAP = bilevel positive airway pressure; CMO = comfort measures only; COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19– Associated Hospitalization Surveillance Network; CPAP = continuous positive airway pressure; DNI = do not intubate; DNR = do not resuscitate; ICU = intensive care unit; IQR = interguartile range; LTCF = long-term care facility

<sup>a</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah

<sup>b</sup>Statistical significance for univariate analyses was determined as p<.10

<sup>c</sup>Race and Hispanic ethnicity: Data on race and ethnicity were categorized as follows: Hispanic or Latino, non-Hispanic White (White), non-Hispanic Black (Black), and Other/Unknown. If ethnicity was unknown (7% of cases), non-Hispanic ethnicity was assumed.

<sup>d</sup>Includes American Indian/Alaska Native (68, 1%), Asian/Pacific Islander (240, 7%), and multiple/unknown race (168, 3%). For adults aged <65 years, the breakdown was: American Indian/Alaska Native (50, 1%), Asian/Pacific Islander (164, 7%), and multiple/unknown race (117, 4%). For those aged ≥65 years, American Indian/Alaska Native (18, 1%), Asian/Pacific Islander (76, 7%), and multiple/unknown race (51, 2%).

<sup>e</sup>Long-term care facility (LTCF) residence was defined as residence in rehabilitation facilities, assisted living/residential care, group homes, nursing homes, skilled nursing facilities, long-term care facilities, long-term acute care hospitals, residential care facilities or other long-term care facilities.

<sup>f</sup>Obesity is defined as calculated body mass index (BMI) ≥30 kg/m2, and if BMI is missing, by International Classification of Diseases discharge diagnosis codes. <sup>g</sup>Cardiovascular disease excludes hypertension.

<sup>h</sup>Overall condition categories as defined in Supplementary Table 1.

# Figures

Figure 1. Multivariable model<sup>a</sup> assessing factors associated with full vaccination status in hospitalized adults with laboratory-confirmed COVID-19-associated hospitalization admitted January 1 – June 30, 2021, restricting to those with COVID-19-associated hospitalization as the likely primary reason for admission, among those aged A) <65 years and B) aged  $\geq$ 65 years — COVID-NET, 13 States<sup>b</sup> A)

	Unv	accinated	Fully	vaccinated	Unad	djusted Risk Ratio	Adjust Ra	ed Risk atio									
Demographic characteristic	Ν	Weighted %	N	Weighted %	RR	(95% Cl)	aRR	(95% CI)	p- value	Standard error							
											-						
Age (in years)							1	(0.98, 1.02)	0.81	0.0093		•					
Sex											_						
Male	1,576	50.3	40	43.7	0.77	(0.55, 1.09)	0.77	(0.57, 1.05)	0.10	0.1537							
Female	1,463	49.7	52	56.3	Ref		Ref										
Race and Hispanic ethnicity $^{\circ}$																	
White	1347	37.9	60	61.7	Ref		Ref				-•	-					
Black	785	33.4	11	14.8	0.28	(0.09, 0.81)	0.26	(0.09, 0.75)	0.01	0.5394	-•	•					
Hispanic or Latino	581	17.1	16	18.6	0.68	(0.5, 0.92)	0.76	(0.54, 1.07)	0.12	0.1741	-	_	•				
Other/Unknown <sup>d</sup>	326	11.7	5	4.9	0.26	(0.1, 0.72)	0.33	(0.12, 0.94)	0.04	0.5272		_	_				
LTCF residence <sup>e</sup>	44	1.8	5	5.0	2.85	(1.23, 6.6)	1.72	(0.67, 4.43)	0.26	0.4834		•					
Underlying medical condition													•				
Chronic lung disease	875	30.1	35	40.8	1.59	(1.1, 2.3)	1.26	(0.99, 1.6)	0.06	0.1216			•				_
Cardiovascular disease <sup>f</sup>	606	20.7	29	31.7	1.77	(0.93, 3.36)	1.17	(0.64, 2.15)	0.60	0.3094				)			
Neurologic disease	327	10.5	18	22.9	2.5	(1.64, 3.8)	1.62	(1, 2.61)	0.05	0.2433			•				
Renal disease	259	10.3	15	18.2	1.92	(1.02, 3.61)	1.56	(0.79, 3.09)	0.20	0.3484	0	1	2	3		4	5
Immunosuppressive condition	275	10.1	22	23.8	2.74	(1.24, 6.03)	2	(0.85, 4.72)	0.11	0.4384			a	RR (95	% CI)		

Gastrointestinal or liver disease	181	5.1	11	15.0	3.18	(1.38, 7.36)	2.35	(1.02, 5.4)	0.04	0.425			
Blood disorder	90	2.2	5	6.1	2.83	(1.09, 7.33)	1.7	(0.71, 4.12)	0.24	0.4496			

Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19–Associated Hospitalization Surveillance Network; LTCF = long-term care facility <sup>a</sup>Log-linked Poisson Regression using generalized estimating equations (GEE) clustered on site with independent covariance structure. Statistical significance was determined at p<0.05.

<sup>b</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

<sup>c</sup>Race/ethnicity: Data on race and ethnicity were categorized as follows: non-Hispanic White (White), non-Hispanic Black (Black), Other/Unknown. If ethnicity was unknown (7%), non-Hispanic ethnicity was assumed.

<sup>d</sup>Includes American Indian/Alaska Native (50), Asian/Pacific Islander (164), and multiple/unknown race (117).

<sup>e</sup>Long-term care facility (LTCF) residence was defined as residence in rehabilitation facilities, assisted living/residential care, group homes, nursing homes, skilled nursing facilities, long-term care facilities, long-term acute care hospitals, residential care facilities or other long-term care facilities.

<sup>f</sup>Cardiovascular disease excludes hypertension.

	Unva	accinated	l vac	ully cinated	Una	djusted Risk Ratio	Adjuste	d Risk Ratio									
Demographic characteristic	N	Weight ed %	N	Weight ed %	RR	(95% CI)	aRR	(95% Cl)	p- value	Standard error							
Age (in years)							1.03	(1, 1.07)	0.04	0.0162		•					
Sex																	
Male	699	53.5	105	51.1	0.91	(0.68, 1.23)	0.84	(0.64, 1.11)	0.22	0.1397							
Female	702	46.5	95	48.9	Ref		Ref										
Race and Hispanic ethnicity <sup>c</sup>																	
White	916	57.4	144	67.8	Ref		Ref										
Non-Hispanic Black	238	23.4	24	18.5	0.68	(0.46, 1)	0.78	(0.51, 1.19)	0.25	0.2171		•					
Hispanic or Latino	120	8.2	14	5.7	0.61	(0.27, 1.37)	0.81	(0.36, 1.81)	0.61	0.4092		•	_				
Other/Unknown <sup>d</sup>	127	11	18	8	0.63	(0.38, 1.07)	0.65	(0.35, 1.23)	0.18	0.3227							
LTCF residence	102	10.9	32	17.7	1.69	(1.21, 2.37)	1.21	(0.86, 1.7)	0.27	0.1731			)				
Underlying medical condition																	
Obesity <sup>f</sup>	539	37.8	75	47.9	1.48	(0.93, 2.33)	1.6	(1.02, 2.5)	0.04	0.2282			_				
Chronic lung disease	477	31.1	71	38.6	1.37	(0.94, 2)	1.25	(0.81, 1.94)	0.31	0.2218							
Cardiovascular disease <sup>g</sup>	741	57.3	128	67.5	1.52	(0.9, 2.55)	1.12	(0.69, 1.82)	0.65	0.2487				•			
Neurologic disease	334	27	64	36.4	1.51	(1.12, 2.05)	1.35	(0.98, 1.86)	0.07	0.1647		•					
Renal disease	325	25.4	74	34.5	1.51	(1.09, 2.09)	1.24	(0.8, 1.92)	0.34	0.223	0	1	2	3	4	5	6
Immunosuppressive condition	167	13.2	47	34.9	3.21	(2.21, 4.67)	3.16	(1.96, 5.11)	<.001	0.245			aR	R (95% C	1)		
Rheumatologic or autoimmune disease	59	3.9	21	10.1	2.55	(1, 6.52)	1.3	(0.56, 3.04)	0.54	0.4317	T						

Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19–Associated Hospitalization Surveillance Network; LTCF = long-term care facility <sup>a</sup>Log-linked Poisson Regression using generalized estimating equations (GEE) clustered on site with independent covariance structure

<sup>b</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

<sup>c</sup>Race and Hispanic ethnicity: Data on race and ethnicity were categorized as follows: non-Hispanic White (White), non-Hispanic Black (Black), Other/Unknown. If ethnicity was unknown (7%), non-Hispanic ethnicity was assumed.

<sup>d</sup>Includes American Indian/Alaska Native (18), Asian/Pacific Islander (76), and multiple/unknown race (51)

<sup>e</sup>Long-term care facility (LTCF) residence was defined as residence in rehabilitation facilities, assisted living/residential care, group homes, nursing homes, skilled nursing facilities, long-term care facilities, long-term acute care hospitals, residential care facilities or other long-term care facilities.

<sup>†</sup>Obesity is defined as calculated body mass index (BMI) ≥30 kg/m2, and if BMI is missing, by International Classification of Diseases discharge diagnosis codes. <sup>g</sup>Cardiovascular disease excludes hypertensio





# A)



Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19–Associated Hospitalization Surveillance Network

<sup>a</sup>Number of patients with laboratory-confirmed COVID-19–associated hospitalizations per 100,000 population.

<sup>b</sup> COVID-NET hospitalization data are preliminary and subject to change as more data become available. In particular, rates for recent hospital admissions are subject to lag.

<sup>c</sup>California, Colorado, Connecticut, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah

Figure 3. Age-specific population-based rates<sup>a</sup> of COVID-19-associated hospitalizations among unvaccinated and fully vaccinated adults aged ≥18 years admitted January 24–July 24, 2021, <sup>b</sup> by week of admission and aged A) 18–49 years B) 50–64 years and C) ≥65 years — COVID-NET, 13 States<sup>c</sup>. Rates are shown with 95% confidence intervals.







Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19–Associated Hospitalization Surveillance Network

<sup>a</sup>Number of patients with laboratory-confirmed COVID-19–associated hospitalizations per 100,000 population. Lighter shades around each line represent 95% confidence intervals

<sup>b</sup> COVID-NET hospitalization data are preliminary and subject to change as more data become available. In particular, rates for recent hospital admissions are subject to lag.

<sup>c</sup> California, Colorado, Connecticut, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

# **Supplementary Content**

## Supplementary Tables:

# Supplement Table 1. Categorization of Underlying Medical Conditions<sup>a</sup>

Chronic Lung Disease	Active tuberculosis
	Achartasis
	• Asbestosis
	Asthma/Reactive alrway disease
	Bronchiectasis
	Bronchiolitis obliterans
	Chronic bronchitis
	Chronic respiratory failure
	Cystic fibrosis
	Emphysema/Chronic Obstructive Pulmonary Disease
	Interstitial lung disease
	Obstructive sleep appea
	Oxygen dependent
	Bulmonary fibrosis
	Putitionary fibrosis
	Restrictive lung disease
	• Sarcoldosis
Diabetes Mellitus	
Other Chronic Metabolic Disease (except	Adrenal Disorders (Addison's, Adrenal Insufficiency, Cushing
Diabetes Mellitus)	Syndrome, Congenital Adrenal Hyperplasia)
	Glycogen or other storage diseases
	Hyper/Hypo function of pituitary gland
	Inborn errors of metabolism
	Metabolic Syndrome
	Parathyroid Dysfunction (Hyperparathyroidism,
	Hypoparathyroidism)
	• Thyroid dysfunction (Grave's disease, Hashimoto's Disease.
	Hyperthyroidism, Hypothyroidism)
Blood Disorders/Hematologic Conditions	Alpha thalassemia
	Anlastic anemia
	Beta thalassemia
	Coogula nathy (Easter V) Leiden, Ven Willebrand Disease)
	Coaguiopathy (Pattor v Leiden, von whiebrand Disease)
	Hemoglobin S-beta thalassemia
	• Leukopenia
	Myelodysplastic syndrome
	Neutropenia
	Pancytopenia
	Polycythemia vera
	Sickle cell disease
	Splenectomy/Asplenia
	Thrombocytopenia
Cardiovascular Disease (except	Aortic aneurysm, history of
hypertension)	Aortic/Mitral/Tricuspid/Pulmonic valve replacement, history of
	Aortic regurgitation
	Aortic stenosis
	Atheroscleratic cardiovascular dispaso
	Attrial fibrillation
1	

	Atrioventricular blocks
	<ul> <li>Automated implantable devices/Pacemaker</li> </ul>
	Bundle branch block
	Cardiomyopathy
	Carotid stenosis
	<ul> <li>Cerebral vascular accident/Incident/Stroke, history of</li> </ul>
	Congenital heart disease
	<ul> <li>Coronary artery bypass grafting, history of</li> </ul>
	Coronary artery disease
	<ul> <li>Deep vein thrombosis, history of</li> </ul>
	<ul> <li>Heart failure/congestive heart failure</li> </ul>
	Myocardial infarction, history of
	<ul> <li>Mitral regurgitation</li> </ul>
	Mitral stenosis
	Peripheral artery disease
	Peripheral vascular disease
	Pulmonary embolism, history of
	Pulmonary hypertension
	Pulmonic regurgitation
	Pulmonic stenosis
	• Transient ischemic attack, history of
	Tricuspid regurgitation
	Tricuspid stenosis
	• Ventricular fibrillation, history of
	Ventricular tachycardia, history of
Hypertension	
Neurologic Disorder	Amyotrophic lateral sclerosis
	Cerebral palsy
	Cognitive dysfunction
	Dementia/Alzheimer's disease
	Developmental delay
	Down syndrome/Trisomy 21
	Edward's syndrome/Trisomy 18
	• Epilepsy/seizure/seizure disorder
	Mitochondrial disorder
	Multiple sclerosis
	Muscular dystrophy
	Myasthenia gravis
	Neural tube defects/Spina bifida
	Neuropathy
	• Parkinson's disease
	Plegias/Paralysis/Quadriplegia
	• Scoliosis/Kyphoscoliosis
	• Traumatic brain injury, history of
History of Guillain-Barre Syndrome	· · ·
Immunocompromised Conditions	• AIDS or CD4 count <200
	Complement deficiency
	Graft vs. host disease
	HIV Infection
	<ul> <li>Immunoglobulin deficiency/Immunodeficiency</li> </ul>

	• Immunosuppressive therapy (within the last 12 months prior to
	admission)
	• Leukemia <sup>b</sup>
	<ul> <li>Lymphoma/Hodgkins/Non-Hodgkins<sup>b</sup></li> </ul>
	Metastatic cancer <sup>b</sup>
	Multiple myeloma <sup>b</sup>
	• Solid organ malignancy <sup>b</sup>
	• Steroid therapy (within 2 weeks of admission)
	• Transplant, hematopoietic stem cell (Bone marrow transplant,
	peripheral stem cell transplant), history of
	• Transplant, solid organ, history of
Renal Disease	Chronic kidney disease/chronic renal insufficiency
	• Dialvsis
	• End stage renal disease
	Glomerulonephritis
	Nenhrotic syndrome
	Polycystic kidney disease
Gastrointestinal/Liver Disease	Alcoholic hepatitis
	Autoimmune benatitis
	Barrett's esonbagitis
	Chronic liver disease
	Chronic nancreatitis
	Cirrhosis/End stage liver disease
	Crohn's disease
	Econhageal varices
	Esophageal strictures
	Esophageal structures
	Hepatitis D, chronic
	Non alcoholic fatty liver disease /Non alcoholic steatehonatitis
	Non-alconolic fatty liver disease/ Non-alconolic steatone patitis
Rheumatologic/Autoimmune Conditions	Anloyloging spondulitis
Aneumatologic/Autoininiune conditions	Ankylosing spondylitis     Dermatemylositis
	Dermatomyositis
	Kawasaki usease
	Microscopic polyangilits     Delivertexitie redesure
	Polyartentis houosum     Delyartentis houosum
	PolyInyositis     Descriptio arthritic
	Psonauc arthritis     Dhouracte id orthritic
	Kneumatold artnnits     Sustaining Lunus
	Systemic Lupus Erythematosus/Lupus     Sustemic selevesis
	Systemic sciences
	Tomporal /Giant Coll artoritic
	Vassulitie, ether
Other specify	Vasculius, other
Other, specify	<ul> <li>Post-partum (2 weeks or less)</li> <li>Ecoding tube dependent</li> </ul>
	recalling tube dependent     Trachastomy dependent (contilator dependent)
	Moolebair dependent
	<ul> <li>wneelchair dependent</li> <li>Free text field for other underhäum medicient er discher dittien.</li> </ul>
	<ul> <li>Free text field for other underlying medical conditions that</li> </ul>

were not specified above

<sup>a</sup>Underlying medical conditions were selected before hospitalization surveillance began.

<sup>b</sup>Current/in treatment or diagnosed in previous 12 months

Supplementary Table 2. Characteristics of fully vaccinated cases who had a prior positive SARS-CoV-2 test compared with fully vaccinated cases with no evidence of prior infection, among adults ≥ 18 years admitted January 1–June 30, 2021 — COVID-NET, 13 States<sup>a</sup>

Characteristics	No evidence of prior	Prior positive test	p-value <sup>c</sup>
	infection	n=47 <sup>6</sup>	
	n=292		
Age group			0.82
18-49 years	29 (8.7)	4 (5.9)	
50-64 years	63 (16.3)	11 (18.6)	
≥65 years	200 (75.0)	32 (75.5)	
Sex			0.77
Male	145 (49.3)	26 (45.4)	
Female	147 (50.7)	21 (54.6)	
Race and Hispanic ethnicity <sup>d</sup>			
White	204 (66.3)	33 (69.9)	0.10
Black	35 (17.5)	7 (15.5)	
Hispanic or Latino	30 (9.0)	4 (9.4)	
Other/Unknown	23 (7.2)	3 (5.2)	
Month of admission			0.08
January	1 (0.6)	0 (0.0)	
February	2 (1.6)	0 (0.0)	
March	18 (13.0)	5 (37.1)	
April	39 (34.2)	7 (21.8)	
May	99 (31.2)	13 (22.7)	
June	133 (19.3)	22 (18.4)	
Code status on admission			0.62
Full code	222 (74.5)	36 (82.5)	
DNR/DNI/CMO	47 (17.3)	9 (10.9)	
Unknown	23 (8.2)	2 (6.6)	
LTCF residence <sup>e</sup>	37 (14.5)	16 (31.6)	0.07
Any symptom	250 (88.2)	35 (65.0)	0.02
Hypertension	202 (70.5)	33 (75.6)	0.61
Obesity <sup>f</sup>	121 (48.4)	15 (46.5)	0.90
Severe obesity <sup>g</sup>	34 (14.1)	5 (8.9)	0.39
Chronic metabolic disease	142 (48.5)	23 (63.6)	0.20
Diabetes mellitus	106 (38.1)	18 (53.5)	0.23
Chronic lung disease	106 (39.2)	23 (43.7)	0.72
Asthma/Reactive airway disease	46 (18.7)	10 (18.8)	0.99
COPD	43 (14.2)	11 (21.7)	0.36
Cardiovascular disease <sup>h</sup>	157 (58.6)	30 (78.0)	0.04
Heart failure	57 (24.6)	17 (34.1)	0.40
Coronary artery disease	58 (18.6)	12 (19.1)	0.94
Neurologic disease	82 (33.0)	18 (31.9)	0.92
Renal disease	89 (30.4)	14 (21.2)	0.32

Characteristics	No evidence of prior	Prior positive test	p-value <sup>c</sup>
	infection	n=47 <sup>b</sup>	
	n=292		
Immunosuppressive condition	69 (32.1)	6 (9.8)	0.006
Gastrointestinal or liver disease	24 (7.3)	6 (9.6)	0.63
Blood disorder	19 (5.4)	4 (2.8)	0.30
Rheumatologic or autoimmune disease	24 (8.7)	1 (3.0)	0.28
Number of underlying conditions <sup>i</sup>			0.07
0	13(3.6)	0 (0.0)	
1	24 (6.3)	9 (17.3)	
2	54 (19.3)	5 (5.1)	
≥3	201 (70.8)	33 (77.7)	
ICU admission	60 (21.6)	7 (11.4)	0.22
In-hospital death	23 (7.5)	2 (1.2)	0.006
ICU admission or in-hospital death	66 (23.3)	8 (12.0)	0.18
Median length of stay in days (IQR)	5 (3–8)	5 (2–14)	<.001
ICU admission, invasive mechanical	69 (23.9)	10 (34.3)	0.47
ventilation, or in-hospital death			
Invasive mechanical ventilation	25 (8.7)	3 (23.0)	0.23
Vasopressor use	29 (11.0)	5 (4.9)	0.19
BIPAP or CPAP use	44 (14.5)	4 (6.7)	0.31
Renal Replacement Therapy	14 (3.1)	2 (1.2)	0.23

Abbreviations: BIPAP = bilevel positive airway pressure; CMO = comfort measures only; COVID-NET = COVID-19– Associated Hospitalization Surveillance Network; CPAP = continuous positive airway pressure; DNI = do not intubate; DNR = do not resuscitate; ICU = intensive care unit; IQR = interquartile range; LTCF = long-term care facility; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

<sup>a</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah

<sup>b</sup>Five cases with hospitalization not primarily associated with COVID-19 illness were excluded

<sup>c</sup>Statistical significance for univariate analyses was determined as p<.10

<sup>d</sup>Race and Hispanic ethnicity: Data on race and ethnicity were categorized as follows: Hispanic or Latino, non-Hispanic White (White), non-Hispanic Black (Black), and Other/Unknown. If ethnicity was unknown, non-Hispanic ethnicity was assumed.

<sup>e</sup>Long-term care facility (LTCF) residence was defined as residence in rehabilitation facilities, assisted living/residential care, group homes, nursing homes, skilled nursing facilities, long-term care facilities, long-term acute care hospitals, residential care facilities or other long-term care facilities.

<sup>f</sup>Obesity is defined as calculated body mass index (BMI)  $\geq$  30 kg/m2, and if BMI is missing, by International Classification of Diseases discharge diagnosis codes.

<sup>g</sup>Severe obesity is defined as calculated body mass index (BMI) ≥40 kg/m2, and if BMI is missing, by International Classification of Diseases discharge diagnosis codes.

<sup>h</sup>Cardiovascular disease excludes hypertension

<sup>1</sup>Overall condition categories as defined in Supplementary Table 1

Supplementary Table 3A. Multivariable model <sup>®</sup> assessing factors associated with severe COVID-19 diseases (ICU, in-hospital death) in
hospitalized adults with laboratory-confirmed COVID-19-associated hospitalization admitted January 1 – June 30, 2021, restricting to those
with COVID-19-associated hospitalization as the likely primary reason for admission, among those aged <65 years — COVID-NET, 13 States $^{ m b}$

Category	No severe illness	Have severe illness	Unadjusted	Adjusted risk	p-value	Standard
	n (weighted %)	n (weighted %)	risk ratio	ratio		error
Race and Hispanic ethnicity <sup>c</sup>						
White	1,096 (37.2)	311 (42.6)	R	R	R	R
Black	653 (34.9)	143 (26.0)	0.7 (0.5, 1)	0.8 (0.6, 1.1)	0.14	0.1716
Hispanic or Latino	475 (16.7)	122 (18.4)	1 (0.8, 1.2)	1 (0.8, 1.3)	0.78	0.1106
Other/Unknown <sup>d</sup>	249 (11.2)	82 (12.9)	1 (0.8, 1.2)	1.1 (0.9, 1.3)	0.20	0.0815
Sex						
Male	1,237 (49.3)	379 (53.9)	1.2 (1, 1.3)	1.2 (1, 1.3)	0.02	0.0626
Female	1,236 (50.7)	279 (46.1)	R	R	R	R
Age (in years)				1 (1, 1)	0.002	0.0039
Unvaccinated	2,400 (98.7)	639 (98.9)	R	R	R	R
Fully vaccinated	73 (1.3)	19 (1.1)	0.9 (0.7, 1.2)	0.8 (0.6, 1.0)	0.028	0.1283
LTCF residence <sup>e</sup>	34 (1.7)	15 (2.1)	1.2 (0.6, 2.2)	0.9 (0.5, 1.7)	0.74	0.3428
Underlying medical condition						
Chronic metabolic disease	829 (35.1)	288 (46.0)	1.4 (1.2, 1.7)	1.3 (1.1, 1.5)	0.001	0.0823
Chronic lung disease	702 (29.4)	208 (33.6)	1.2 (1, 1.4)	1.1 (0.9, 1.3)	0.48	0.1052
Cardiovascular disease <sup>f</sup>	462 (19.3)	173 (27.1)	1.4 (1.1, 1.8)	1.2 (1, 1.6)	0.11	0.1316
Neurologic disease	261 (10.2)	84 (12.6)	1.2 (1, 1.4)	1 (0.9, 1.2)	0.78	0.0881
Renal disease	191 (9.6)	83 (13.6)	1.4 (1, 1.8)	1.1 (0.9, 1.4)	0.31	0.1202
Immunosuppressive condition	227 (9.7)	70 (12.4)	1.2 (1, 1.5)	1.2 (0.9, 1.5)	0.29	0.1362
Gastrointestinal or liver disease	140 (4.7)	52 (7.8)	1.5 (1.2, 2)	1.4 (1, 2)	0.04	0.1736

Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19–Associated Hospitalization Surveillance Network; LTCF = long-term care facility

<sup>a</sup>Log-linked Poisson Regression using generalized estimating equations (GEE) clustered on site with exchangeable covariance structure

<sup>b</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

<sup>c</sup>Race and Hispanic ethnicity: Data on race and ethnicity were categorized as follows: non-Hispanic White (White), non-Hispanic Black (Black), Other/Unknown. If ethnicity was unknown (4%), non-Hispanic ethnicity was assumed. <sup>d</sup>Includes American Indian/Alaska Native, Asian/Pacific Islander, and multiple/unknown race.

<sup>e</sup>Long-term care facility (LTCF) residence was defined as residence in rehabilitation facilities, assisted living/residential care, group homes, nursing homes, skilled nursing facilities, long-term care facilities, long-term acute care hospitals, residential care facilities or other long-term care facilities.

<sup>f</sup>Cardiovascular disease excludes hypertension.

Supplementary Table 3B. Multivariable model<sup>a</sup> assessing factors associated with severe COVID-19 diseases (ICU, in-hospital death) in hospitalized adults with laboratory-confirmed COVID-19-associated hospitalization admitted January 1 – June 30, 2021, restricting to those with COVID-19-associated hospitalization as the likely primary reason for admission, among those aged ≥65 years — COVID-NET, 13 States<sup>b</sup>

Category	No severe illness n (weighted %)	Have severe illness n (weighted %)	Unadjusted risk ratio	Adjusted risk ratio	p-value	Standard error
Race and Hispanic ethnicity <sup>c</sup>						
White	829 (60.5)	231 (50.0)	R	R	R	R
Black	185 (21.5)	77 (28.4)	1.4 (0.9, 2.3)	1.6 (1, 2.6)	0.05	0.2433
Hispanic or Latino	89 (7.4)	45 (10.1)	1.4 (1, 2.1)	1.6 (1.2, 2.3)	0.005	0.1736
Other/Unknown <sup>d</sup>	101 (10.6)	44 (11.5)	1.2 (0.9, 1.7)	1.3 (0.9, 1.8)	0.15	0.1722
Sex						
Male	576 (52.5)	228 (55.9)	1.1 (0.8, 1.5)	1.1 (0.8, 1.4)	0.47	0.1326
Female	628 (47.5)	169 (44.1)	R	R	R	R
Age (in years)				1 (1, 1)	0.34	0.0086
Unvaccinated	1,051 (94.8)	350 (94.6)	R	R	R	R
Fully vaccinated	153 (5.2)	47 (5.4)		1.1 (0.7, 1.6)	0.80	0.2167
LTCF residence <sup>®</sup>	90 (10.3)	44 (14.2)	1.3 (0.9, 1.9)	1.5 (1, 2.2)	0.06	0.2019
Underlying medical condition						
Neurologic disease	304 (29.0)	94 (22.5)	0.8 (0.6, 1)	0.7 (0.5, 0.9)	0.02	0.1486
Immunosuppressive condition	155 (13.0)	59 (18.5)	1.4 (1.1, 1.7)	1.4 (1.1, 1.7)	0.002	0.1097

Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19–Associated Hospitalization Surveillance Network; LTCF = long-term care facility <sup>a</sup>Log-linked Poisson Regression using generalized estimating equations (GEE) clustered on site with exchangeable covariance structure

<sup>b</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

<sup>c</sup>Race and Hispanic ethnicity: Data on race and ethnicity were categorized as follows: non-Hispanic White (White), non-Hispanic Black (Black), Other/Unknown. If ethnicity was unknown (7% of cases), non-Hispanic ethnicity was assumed.

<sup>d</sup>Includes American Indian/Alaska Native, Asian/Pacific Islander, and multiple/unknown race

<sup>e</sup>Long-term care facility (LTCF) residence was defined as residence in rehabilitation facilities, assisted living/residential care, group homes, nursing homes, skilled nursing.

# Supplementary Table 4. Rate ratios of COVID-19-associated hospitalizations in unvaccinated vs vaccinated patients among all adults aged ≥18 years and by age group <sup>a</sup>, January 24–July 24, 2021<sup>b</sup>– COVID-NET, 13 States<sup>c</sup>

	Rate ratio of hospitalizations	Rate ratio,	Rate ratio,	Rate ratio,
NANA/D	all adults 218 years (age-adjusted)	18–49 years	50–64 years	≥65 years
MINWR week ending	24			
1/30/2021	21	-	/	-
2/6/2021	13	-	-	/
2/13/2021	8	10	26	5
2/20/2021	8	23	21	4
2/27/2021	6	15	23	4
3/6/2021	14	21	15	11
3/13/2021	10	52	14	6
3/20/2021	12	15	12	11
3/27/2021	20	21	22	18
4/3/2021	15	75	15	11
4/10/2021	17	45	22	13
4/17/2021	28	18	53	25
4/24/2021	24	40	51	16
5/1/2021	22	33	31	17
5/8/2021	31	51	33	26
5/15/2021	26	32	49	18
5/22/2021	19	13	23	21
5/29/2021	21	19	16	25
6/5/2021	29	24	78	23
6/12/2021	15	17	21	13
6/19/2021	17	13	25	16
6/26/2021	17	12	16	22
7/3/2021	14	13	18	12
7/10/2021	12	19	13	10
7/17/2021	17	17	20	15
7/24/2021	19	20	25	16
Cumulative	17	23	22	13
Range	6–31	10-75	7–78	4–26

Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19–Associated Hospitalization Surveillance Network

<sup>a</sup>Age-specific rate ratios could not be calculated for weeks during which zero vaccinated cases were reported and are represented by a dash (-).

<sup>b</sup> COVID-NET hospitalization data are preliminary and subject to change as more data become available. In particular, rates for recent hospital admissions are subject to lag.

<sup>c</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

#### Supplementary Figures:

Supplementary Figure 1. Selection of cases for analysis of adults ≥18 years with laboratory-confirmed COVID-19-associated hospitalization admitted January 1 – June 30, 2021, by vaccination status — COVID-NET, 13 States<sup>a</sup>



**4,732** hospitalized adults ≥18 years admitted due to COVID-19 related illness (Comparison Sample)<sup>e</sup>:

- Unvaccinated (n = 4,440)
- Fully vaccinated (n = 292)

Abbreviation: COVID-NET, Coronavirus Disease 2019 (COVID-19-associated Hospitalization Surveillance Network)

<sup>a</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah

<sup>b</sup>Vaccine sample includes representative random sample from each site (sampled cases) as well as all non-sampled cases if all cases from a single site and age strata had vaccination status available.

<sup>c</sup>Received one dose of two-dose series (for Pfizer/BioNTech and Moderna)

<sup>d</sup> Includes cases admitted due to obstetrics/labor and delivery admission (316), surgery (103), psychiatric admission needing acute medical care (99), trauma (124), "other" (2) and unknown reason (72).

<sup>e</sup>Comparison sample includes only those sampled cases with complete medical chart abstraction who were either unvaccinated or fully vaccinated; vaccinate cases who had evidence of prior SARS-CoV-2 infection prior to qualifying as fully vaccinated were excluded.

NOTE: For both the vaccine sample and the analytic sample, sampling weights were created based on the probability of selection. Weights were adjusted for non-response, adjusted to population catchment totals based on combinations of surveillance site, time period of admission, age, sex, and race/ethnicity via published raking procedures, and trimmed to reduce variability, as previously described.<sup>1</sup>



Supplementary Figure 2. Proportion of adults ≥18 years with COVID-19-associated hospitalizations admitted January 1 – June 30, 2021 who are fully vaccinated, by age group and month of admission – COVID-NET, 13 States<sup>a</sup>

<sup>a</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah

Supplementary Figure 3. COVID-NET catchment population by vaccination status<sup>a</sup> and week, used as denominator in population-based-rate calculations<sup>b</sup> among A) all adults ≥18 years, B) 18–49 years, C) 50–64 years, and D) ≥65 years, January 24–July 24, 2021—COVID-NET,<sup>c</sup> 13 States<sup>d</sup>



B)







<sup>a</sup> Partially vaccinated persons are excluded.

<sup>b</sup> Data from CDC immunization information systems county-level data for the Coronavirus Disease 2019 (COVID-

19)-Associated Hospitalization Surveillance Network (COVID-NET) surveillance area.

<sup>c</sup> The COVID-NET hospitalization data are preliminary and subject to change as more data become available. Rates for recent hospital admissions are subject to lag.

<sup>d</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah